Converting adult tablets into stable, palatable pediatric oral suspensions under USP <795> nonsterile compounding standards
Extemporaneous compounding begins long before a mortar touches a tablet. Roughly 50-70% of drugs prescribed to hospitalized neonates and infants have no commercially available liquid, chewable, or age-appropriate dosage form (Nahata, Am J Health-Syst Pharm), forcing pharmacists to convert adult tablets into oral suspensions. The first — and most consequential — decision is whether the source tablet can be crushed at all without destroying its intended pharmacokinetics.
The single most important screening question is: how does this tablet release its drug?
• Immediate-release (IR) tablets: drug is dispersed in a rapidly disintegrating matrix (microcrystalline cellulose, lactose, croscarmellose). Crushing simply speeds disintegration that was already fast — no meaningful change to the absorption profile. Captopril 25 mg IR tablets, spironolactone 25 mg IR tablets, and lisinopril 10 mg IR tablets are textbook candidates.
• Enteric-coated (EC) tablets: the coating (commonly methacrylic acid copolymer, Eudragit L100/S100) is pH-dependent and designed to survive gastric acid, dissolving only in the higher-pH duodenum. Omeprazole delayed-release tablets are EC because omeprazole itself is rapidly degraded by gastric acid (t1/2 <2 min at pH 1). Crushing an EC tablet exposes the naked drug to stomach acid and destroys most of the dose before absorption — this is why compounded pediatric omeprazole suspensions are instead made from omeprazole powder (or non-enteric-coated capsule granules) buffered with 8.4% sodium bicarbonate solution, not from crushed enteric tablets.
• Extended-release (ER/SR/XL/CR) tablets: rely on an intact rate-controlling matrix (hydroxypropyl methylcellulose gel matrix, e.g. Procardia XL nifedipine) or an osmotic pump shell (OROS technology) to release drug over 12-24 hours. Crushing ruptures the matrix and delivers the full 24-hour dose at once — a well-documented cause of pediatric overdose. ER products are absolutely excluded from crush-and-suspend compounding; if a sustained profile is clinically required, an alternate IR salt/ester or a compounded controlled-release vehicle must be used instead.
A 2008-2012 series of case reports tied crushed extended-release nifedipine and verapamil tablets to acute pediatric hypotension after caregivers, not pharmacists, crushed the tablets at home. This is precisely the failure mode USP <795> tablet-selection screening is designed to prevent before a formulation ever reaches the patient.
Once release mechanism is cleared, the compounding pharmacist evaluates the tablet's excipient burden and the API's physicochemical behavior in an aqueous vehicle:
• Solubility and pKa: captopril (pKa 3.7, a thiol-containing ACE inhibitor) is freely water-soluble and prone to oxidative dimerization (disulfide formation) above pH 5 — favoring a mildly acidic vehicle and, historically, ascorbic acid as an antioxidant. Spironolactone is poorly water-soluble (BCS Class II) and is compounded as a fine suspension rather than a true solution, making particle size control critical for dose uniformity. Lisinopril is a stable, water-soluble lysine-ester ACE inhibitor with comparatively benign suspension behavior.
• Tablet excipients that interfere with suspending: talc and magnesium stearate (lubricants) can impair wetting; colored film coats (e.g., Opadry) contribute inert pigment that must be accounted for as insoluble matter, not mistaken for undissolved API.
• Compatibility screening tools: differential scanning calorimetry (DSC) and FTIR are used in formal compatibility studies to detect API-excipient interactions (new endotherms, carbonyl shifts) before a formulation is finalized; most community and hospital pharmacies instead rely on published stability-indicating HPLC literature (Trissel's Stability of Compounded Formulations; American Journal of Health-System Pharmacy stability series) rather than performing DSC/FTIR in-house.
• Therapeutic index and dosing precision: narrow therapeutic index drugs (e.g., digoxin) demand tighter content-uniformity tolerances and are generally poor candidates for tablet-crush compounding when a commercial oral solution already exists.
Converting a crushed tablet into a pharmaceutically elegant suspension is a mechanical and formulation science problem simultaneously. The powder must be reduced to a narrow, fine particle-size distribution, incorporated without loss or segregation, and suspended in a vehicle engineered to resist both physical settling and chemical degradation — all performed on a compounding bench under USP <795> nonsterile compounding controls.
The compounding process follows a standardized mechanical sequence performed in a dedicated nonsterile compounding area per USP <795> (and segregated from any hazardous-drug workflow governed by USP <800>):
1. Trituration: tablets are reduced to a fine powder in a glass or Wedgwood mortar using a pestle, applying firm rotary and levigating pressure. Glass mortars are preferred for non-abrasive, non-porous API surfaces; Wedgwood (unglazed porcelain) mortars provide more aggressive size reduction for harder tablets.
2. Comminution endpoint: particle size is reduced until the powder passes a #100 mesh sieve (~150 µm openings) with the practical target closer to 45-75 µm — small enough to avoid a gritty mouthfeel and to minimize differential settling rates between particles of different sizes (Stokes' Law: settling velocity scales with the square of particle radius).
3. Geometric dilution: the fine drug powder is never simply dumped into the full volume of vehicle — doing so risks poor wetting and an inhomogeneous suspension. Instead, an approximately equal volume of vehicle is added to the powder in the mortar and triturated to a smooth, lump-free paste; this paste is then progressively diluted by adding successive, doubling volumes of vehicle (paste + equal volume, then + double that volume, and so on) until the full batch volume is reached — ensuring statistically even drug distribution throughout the final suspension.
4. Levigation: poorly wettable, hydrophobic powders (spironolactone) are first levigated with a small amount of vehicle or a wetting agent (e.g., glycerin) to form a smooth paste before dilution, preventing the powder from clumping or floating ("balling") on the vehicle surface.
5. Quantity transfer/rinse: the mortar and pestle are rinsed with additional vehicle, and the rinse is added to the final container, to ensure no drug is lost to the compounding equipment — critical for narrow-therapeutic-index or low-dose pediatric preparations.
Commercial co-branded vehicle systems dominate pediatric extemporaneous compounding because they are pre-formulated, pre-preserved, and supported by published stability data for dozens of APIs:
• Ora-Plus (Perrigo): a thixotropic suspending vehicle built on microcrystalline cellulose and sodium carboxymethylcellulose (CMC), carrageenan, xanthan gum, and simethicone (an antifoaming agent). It has no sweetener or flavor and is not meant to be dispensed alone — its role is to provide viscosity, structure, and physical suspension of insoluble drug particles (a Bingham plastic / thixotropic rheology that suspends particles at rest but flows easily under shaking or pouring shear).
• Ora-Sweet / Ora-Sweet SF: a flavored, buffered syrup vehicle (sucrose-based standard version; sorbitol/saccharin-based sugar-free "SF" version for diabetic or fructose-intolerant patients) that supplies sweetness, citrus-berry flavor, and a mildly acidic buffered pH (~4.2) that favors chemical stability for many ACE inhibitors and other acid-stable APIs while also providing inherent antimicrobial hostility to most bacteria and molds.
• Ora-Blend: the pre-mixed 1:1 combination of Ora-Plus and Ora-Sweet, used directly when both suspending capacity and palatability/sweetness are required in one step — the most common single vehicle cited in published captopril, lisinopril, and spironolactone suspension stability studies.
• SyrSpend SF PH4 / PH4 Alka (Fagron): a methylcellulose-based, sugar-free, dye-free suspending vehicle line offered at two pH points (PH4, acidic, for acid-stable drugs; PH4 Alka, buffered alkaline, for acid-labile drugs such as omeprazole or proton pump inhibitors) — chosen when patients require sugar-free, low-osmolality, or extended-BUD formulations, since SyrSpend SF carries published manufacturer stability data supporting BUDs of 60-90+ days for many APIs.
• Preservative and pH considerations: both Ora-Plus and Ora-Sweet contain methylparaben/propylparaben and potassium sorbate/sodium benzoate preservative systems effective at their formulated pH; combining vehicles with additional aqueous diluents (e.g., purified water to adjust concentration) dilutes preservative effectiveness and is avoided or independently justified with preservative-effectiveness data.
Because captopril's free thiol group oxidizes to an inactive disulfide dimer above roughly pH 5, the ~4.2 buffered pH of Ora-Plus/Ora-Sweet is not a cosmetic choice — it is the single formulation variable most responsible for captopril suspensions achieving 60-day, rather than 14-day, beyond-use dating in published stability studies.
A compounded suspension is only as good as the evidence behind its expiration. USP General Chapter <795> requires that, absent chapter-specified default limits or published stability data, a water-containing oral formulation be assigned a conservative 14-day beyond-use date (BUD) under refrigeration. Extending that BUD to the 60-90 days seen in real pediatric cardiology and nephrology practice requires a validated, stability-indicating HPLC assay run across a real-time (or accelerated) stability protocol.
A "stability-indicating" assay is one proven capable of resolving intact drug from every degradation product it can plausibly form — not merely a potency assay. Method development and validation follow USP General Chapter <1225> (Validation of Compendial Procedures) principles:
1. Forced degradation: aliquots of the API are deliberately stressed — acid hydrolysis (0.1N HCl), base hydrolysis (0.1N NaOH), oxidation (3% H2O2), heat (60-70°C), and photolysis (ICH Q1B light exposure) — to generate the realistic universe of degradation products the method must separate from the parent peak.
2. Chromatographic separation: reverse-phase C18 columns (typically 150-250 mm x 4.6 mm, 3.5-5 µm particle size) with UV detection (captopril ~210-220 nm; many ACE inhibitors 210-215 nm) and a mobile phase of acidified aqueous buffer (phosphate or acetate, pH 2.5-3.5) with acetonitrile or methanol as organic modifier, run isocratically or with a shallow gradient.
3. System suitability and validation parameters: resolution (Rs) between the parent peak and nearest degradant/excipient peak ≥1.5-2.0; theoretical plates >2,000; tailing factor <2.0; assay linearity typically R² >0.999 across 50-150% of nominal concentration; intra-day and inter-day precision (%RSD) <2%; accuracy (recovery) 98-102%.
4. Degradation pathway confirmation for captopril specifically: the principal degradant is the disulfide dimer (captopril disulfide), formed by oxidative dimerization of the free thiol; a validated method must baseline-resolve this dimer peak from the parent captopril peak, since the dimer is pharmacologically far less active as an ACE inhibitor.
A real-time stability protocol for an extemporaneous suspension typically samples at day 0 (baseline), 7, 14, 30, 60, and 90, storing replicate units at both refrigerated (2-8°C) and controlled room temperature (20-25°C) to bracket realistic patient storage conditions — refrigerator at home vs. a diaper bag or backpack during the day.
Degradation of most hydrolytically/oxidatively labile small molecules in aqueous suspension follows apparent first-order kinetics:
C(t) = C0 · e^(−k·t)
where k is the observed first-order rate constant (day⁻¹) obtained by linear regression of ln(concentration) vs. time. Temperature dependence of k follows the Arrhenius relationship; as a practical bench heuristic, compounding stability literature commonly applies a Q10 rule of thumb (rate roughly doubles to triples for every 10°C rise), which is why refrigerated suspensions of the same formulation routinely support 4-6x longer BUDs than room-temperature storage of the identical batch.
Acceptance criteria: a formulation is considered to have reached the end of its usable life when assayed potency falls below 90% of the initial (or labeled) concentration — the same lower bound used for finished pharmaceutical product shelf-life determination — or when a specified degradation product exceeds a defined threshold, whichever occurs first. The BUD is then set at or before the earliest time point at which the lower confidence bound of the stability data crosses 90%, not simply the last time point tested.
Published HPLC stability data for captopril 1 mg/mL oral suspension compounded in Ora-Plus/Ora-Sweet (1:1) has demonstrated ≥90% potency retention through 60 days at both refrigerated and room-temperature storage in amber PET bottles — a striking illustration of how vehicle pH and container choice, not just temperature, drive real-world beyond-use dating far past the USP <795> conservative 14-day default.
Chemical stability alone does not guarantee a safe dose. A suspension can retain 97% of its total potency while still delivering wildly inaccurate individual doses if the drug particles have settled and the bottle is not adequately resuspended before each administration — a failure mode unique to suspensions (vs. true solutions) and one of the leading causes of pediatric compounding dosing errors identified in ASHP and ISMP medication-safety reviews.
Dose-uniformity verification for a compounded suspension mirrors the logic of USP General Chapter <905> (Uniformity of Dosage Units), adapted for a liquid multi-dose container rather than discrete solid units:
1. Baseline (well-mixed) assay: the freshly compounded, thoroughly mixed suspension is sampled and assayed by the validated stability-indicating HPLC method to confirm the batch meets 90-110% of target concentration at time of release — the compounding equivalent of batch release testing.
2. Settled-state sampling: a representative bottle is allowed to stand undisturbed for a defined interval (simulating time on a pharmacy shelf or in a patient's refrigerator between doses), then sampled without shaking from three zones — near the surface (top), mid-column (middle), and just above the container base (bottom) — using a calibrated oral syringe or pipette identical to the one dispensed to the caregiver.
3. Acceptance evaluation: each aliquot's assayed concentration is expressed as percent of label claim. A formulation is considered acceptably uniform if, after proper resuspension (vigorous shaking for the labeled duration), doses drawn from any location fall within 85-115% of label claim — analogous to the acceptance-value logic of USP <905> for solid dosage units, applied here to confirm the suspending vehicle successfully re-disperses settled API.
4. Failure signature: an unshaken or inadequately shaken suspension typically shows a characteristic gradient — bottom aliquots assay high (concentrated sediment) and top aliquots assay low (supernatant depleted of particulate drug) — precisely the pattern that motivates the "shake well" labeling requirement and caregiver counseling on suspensions.
Because true solutions (fully dissolved drug, like most lisinopril suspensions at low concentration in Ora-Blend) are far less prone to settling-driven dosing error than true suspensions (undissolved particulate drug, like spironolactone), formulation strategy directly affects the uniformity risk profile:
• Particle size control: finer, more uniform trituration reduces the variance in settling velocity between particles (Stokes' Law: v ∝ r²), slowing stratification and narrowing the top-to-bottom concentration gradient even before shaking.
• Vehicle rheology: Ora-Plus's thixotropic structure (high viscosity at rest, shear-thinning when agitated) is deliberately engineered to keep particles suspended between doses while still allowing the suspension to pour and measure accurately once shaken — a rheological compromise most simple syrups cannot achieve.
• Dispensing counseling: pharmacists label compounded suspensions with explicit "shake vigorously for at least 10-20 seconds before each use" instructions, dispense an appropriately sized oral dosing syringe (never a household teaspoon), and — for higher-risk narrow-therapeutic-index drugs — may recommend refrigeration to slow settling kinetics between doses in addition to slowing chemical degradation.
• Periodic re-verification: compounding pharmacies performing high volumes of a given pediatric suspension periodically re-run content-uniformity testing as part of ongoing quality assurance, not only during initial formulation development, since raw-material lot changes (e.g., a new lot of source tablets with different excipient ratios) can subtly shift particle size distribution and settling behavior.
A chemically stable, uniformly dosed suspension still fails its therapeutic purpose if a child spits it out, vomits it back up, or a frustrated caregiver simply stops giving it. Palatability is not a cosmetic afterthought in pediatric compounding — it is a clinical variable with measurable effects on adherence, readmission risk, and disease control, and it is the primary reason professional pharmacy compounding of flavored suspensions outperforms informal "crush a tablet in applesauce" workarounds.
For chronic pediatric regimens — captopril or lisinopril for pediatric heart failure and hypertension, spironolactone as a potassium-sparing diuretic in cardiac or hepatic disease — the prescribed dose only matters if it is reliably swallowed and retained multiple times a day, often for months to years. Poor palatability drives several concrete failure modes:
• Partial dosing: a child accepts only part of the volume, and the caregiver has no reliable way to know how much of the intended dose was actually swallowed versus spit out or dribbled.
• Gagging and emesis: bitter or texturally unpleasant suspensions (gritty, poorly wetted particulate drug) can trigger a gag reflex or vomiting shortly after administration, and unlike a missed dose, a caregiver often cannot tell whether a post-dose vomit occurred before or after clinically meaningful absorption — leading to inconsistent re-dosing practices.
• Caregiver-driven workarounds: frustrated caregivers sometimes crush tablets themselves and mix them into food or juice at home without pharmacy input, reintroducing exactly the bioavailability, dose-splitting accuracy, and stability risks that professional extemporaneous compounding was designed to eliminate in the first place.
Compounding pharmacies deploy several converging strategies to make a bitter or off-flavored API tolerable, guided by both sensory science and the chemical compatibility constraints established during vehicle selection:
• Sweetener systems: Ora-Sweet's sucrose base (or sorbitol/saccharin in Ora-Sweet SF) provides a strong, immediate sweet signal that competes with bitterness perception; sweetness intensity is balanced against caloric load and dental-caries risk for long-term regimens.
• Flavor systems: commercial pharmacy flavoring kits (e.g., FLAVORx-style bubblegum, cherry, grape, tutti-frutti concentrates) are added in small, standardized volumes calibrated to mask specific bitterness profiles without altering vehicle pH enough to compromise the stability data established for the base formulation — flavor selection and stability testing are therefore coupled decisions, not independent ones.
• Viscosity and serving temperature: the same thixotropic body that keeps particles suspended (Ora-Plus) also coats the tongue and reduces the surface area/contact time of bitter API with taste receptors; caregivers are frequently counseled to serve suspensions chilled, since cold temperature further blunts bitter taste perception.
• Measured adherence impact: pediatric adherence literature comparing palatable, professionally flavored liquid formulations against unmasked or ad hoc preparations has repeatedly found adherence differences on the order of 20-30 percentage points, with some cohorts reporting nonadherence rates approaching 50-56% for particularly bitter unmasked liquids versus meaningfully lower rates for the same API in a taste-masked, professionally compounded suspension.
The clinical payoff of the entire compounding chain converges here: a captopril suspension that is chemically correct (Stage 1-2), proven stable over its labeled BUD (Stage 3), and uniformly dosed from every aliquot (Stage 4) still depends on Stage 5 — whether an infant with heart failure will actually accept and keep down a cherry-Ora-Sweet dose twice or three times a day, week after week, for as long as the cardiology regimen requires.